Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant Klebsiella pneumoniae belonging to high-risk clones ST11 and ST16 in South America

Autor(es):Mostrar menos -

Vasquez-Ponce, Felipe ; Bispo, Jessica ; Becerra, Johana ; Fontana, Herrison ; Pariona, Jesus G. M. ; Esposito, Fernanda ; Fuga, Bruna ; Oliveira, Flavio A. ; Brunetti, Florencia ; Power, Pablo ; Gutkind, Gabriel ; Schreiber, Angelica Zaninelli ; Lincopan, Nilton

• Tipo de documento: Artigo Científico
• Fonte: MICROBIOLOGY SPECTRUM; v. N/A, p. 9-pg., 2023-09-06.

Resumo

Two novel variants of Klebsiella pneumoniae carbapenemase (KPC) associated with resistance to ceftazidime-avibactam (CZA) and designated as KPC-113 and KPC-114 by NCBI were identifiedidentified in 2020, in clinical isolates of Klebsiella pneumoniae in Brazil. While K. pneumoniae of ST16 harbored the bla(KPC- 113) variant on an IncFII-IncFIB plasmid, K. pneumoniae of ST11 carried the blaKPC- 114 variant on an IncN plasmid. Both isolates displayed resistance to broad-spectrum cephalosporins, ss-lactam inhibitors, and ertapenem and doripenem, whereas K. pneumoniae producing KPC-114 showed susceptibility to imipenem and meropenem. Whole-genome sequencing and in silico analysis revealed that KPC-113 presented a Gly insertion between Ambler positions 264 and 265 (R264_A265insG), whereas KPC-114 displayed two amino acid insertions (Ser-Ser) between Ambler positions 181 and 182 (S181_P182insSS) in KPC-2, responsible for CZA resistance profiles. Our results confirmconfirm the emergence of novel KPC variants associated with resistance to CZA in international clones of K. pneumoniae circulating in South America. IMPORTANCE KPC-2 carbapenemases are endemic in Latin America. In this regard, in 2018, ceftazidime-avibactam (CZA) was authorized for clinical use in Brazil due to its significant activity against KPC-2 producers. In recent years, reports of resistance to CZA have increased in this country, limiting its clinical application. In this study, we report the emergence of two novel KPC-2 variants, named KPC-113 and KPC-114, associated with CZA resistance in Klebsiella pneumoniae strains belonging to high-risk clones ST11 and ST16. Our finding suggests that novel mutations in KPC-2 are increasing in South America, which is a critical issue deserving active surveillance. (AU)

• Processo FAPESP: 19/15578-4 - Viruloma e patogenicidade de linhagens bacterianas prioritárias em saúde única resistentes a carbapenêmicos e polimixinas
• Beneficiário: Fernanda Ribeiro dos Santos Esposito
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/08224-9 - One Health Brazilian Resistance (OneBR): base genômica integrada para vigilância, diagnóstico e tratamento da resistência aos antimicrobianos na interface humana-ambiente-animal, no Brasil
• Beneficiário: Nilton Erbet Lincopan Huenuman
• Modalidade de apoio: Auxílio à Pesquisa - Regular